Anaplastic lymphoma kinase explained

Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246) is an enzyme that in humans is encoded by the ALK gene.[1] [2]

Identification

Anaplastic lymphoma kinase (ALK) was originally discovered in 1994[3] in anaplastic large-cell lymphoma (ALCL) cells. ALCL is caused by a (2;5)(p23:q35) chromosomal translocation that generates the fusion protein NPM-ALK, in which the kinase domain of ALK is fused to the amino-terminal part of the nucleophosmin (NPM) protein. Dimerization of NPM constitutively activates the ALK kinase domain.

The full-length protein ALK was identified in 1997 by two groups.[4] [5] The deduced amino acid sequences revealed that ALK was a novel receptor tyrosine kinase (RTK), having an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain. While the tyrosine kinase domain of human ALK shares a high degree of similarity with that of the insulin receptor, its extracellular domain is unique among the RTK family in containing two MAM domains (meprin, A5 protein and receptor protein tyrosine phosphatase mu), an LDLa domain (low-density lipoprotein receptor class A) and a glycine-rich region.[6] Based on overall homology, ALK is closely related to the leukocyte receptor tyrosine kinase (LTK) and, together with the insulin receptor, forms a subgroup in the RTK superfamily. The human ALK gene encodes a protein 1,620 amino acids long with a molecular weight of 180 kDa.

Since the original discovery of the receptor in mammals, several orthologs of ALK have been identified: dAlk in the fruit fly (Drosophila melanogaster) in 2001, scd-2 in the nematode (Caenorhabditis elegans) in 2004,[7] and DrAlk in the zebrafish (Danio rerio) in 2013.[8]

The ligands of the human ALK/LTK receptors were identified in 2014:[9] [10] [11] FAM150A (AUGβ) and FAM150B (AUGα), two small secreted peptides that strongly activate ALK signaling. In invertebrates, ALK-activating ligands are Jelly belly (Jeb) in Drosophila,[12] [13] and hesitation behaviour 1 (HEN-1) in C. elegans.[14] No such ligands have been reported yet in zebrafish or other vertebrates.

Mechanism

Following binding of the ligand, the full-length receptor ALK dimerizes, changes conformation, and autoactivates its own kinase domain, which in turn phosphorylates other ALK receptors in trans on specific tyrosine amino acid residues. ALK phosphorylated residues serve as binding sites for the recruitment of several adaptor and other cellular proteins, such as GRB2,[15] IRS1,[16] Shc,[17] Src,[18] FRS2, PTPN11/Shp2,[19] PLCγ,[20] PI3K,[21] and NF1.[22] Other reported downstream ALK targets include FOXO3a,[23] CDKN1B/p27kip,[24] cyclin D2, NIPA,[25] [26] RAC1,[27] CDC42,[28] p130CAS,[29] SHP1,[30] and PIKFYVE.[31]

Phosphorylated ALK activates multiple downstream signal transduction pathways, including MAPK-ERK, PI3K-AKT, PLCγ, CRKL-C3G, and JAK-STAT.[32] [33]

Function

The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system. This observation is based on the extensive expression of ALK messenger RNA (mRNA) throughout the nervous system during mouse embryogenesis.[34] In vitro functional studies have demonstrated that ALK activation promotes neuronal differentiation of PC12[35] [36] [37] or neuroblastoma cell lines.

ALK is critical for embryonic development in Drosophila. Flies lacking the receptor die due to failure of founder cell specification in embryonic visceral muscle.[38] However, while ALK knockout mice exhibit defects in neurogenesis and testosterone production, they remain viable, suggesting that ALK is not critical to their developmental processes.[39] [40] [41]

ALK regulates retinal axon targeting,[42] growth and size,[43] synapse development[7] at the neuromuscular junction,[44] [45] behavioral responses to ethanol,[46] [47] [48] [49] and sleep.[50] It restricts and constrains learning and long-term memory[51] and small-molecule inhibitors of the ALK receptor can improve learning, long-term memory, and extend healthy lifespan.[52] ALK is also a candidate thinness gene, as its genetic deletion leads to resistance to diet- and leptin-mutation-induced obesity.[53] [54]

Pathology

The ALK gene can be oncogenic in three ways – by forming a fusion gene with any of several other genes, by gaining additional gene copies or with mutations of the actual DNA code for the gene itself.

Anaplastic large-cell lymphoma

The 2;5 chromosomal translocation is associated with approximately 60% of anaplastic large-cell lymphomas (ALCLs), type ALK-positive anaplastic large cell lymphoma and very rare cases of ALCL type primary cutaneous anaplastic large cell lymphoma. The translocation creates a fusion gene consisting of the ALK (anaplastic lymphoma kinase) gene and the nucleophosmin (NPM) gene: the 3' half of ALK, derived from chromosome 2 and coding for the catalytic domain, is fused to the 5' portion of NPM from chromosome 5. The product of the NPM-ALK fusion gene is oncogenic.In a smaller fraction of ALCL patients, the 3' half of ALK is fused to the 5' sequence of TPM3 gene, encoding for tropomyosin 3. In rare cases, ALK is fused to other 5' fusion partners, such as TFG, ATIC, CLTC1, TPM4, MSN, ALO17, MYH9.[55]

Adenocarcinoma of the lung

The EML4-ALK fusion gene is responsible for approximately 3-5% of non-small-cell lung cancer (NSCLC). The vast majority of cases are adenocarcinomas. Patients with this ALK rearrangement have the following clinicopathologic characteristics: Young age at diagnosis (median 50 years), female gender, nonsmoker/light smoker, adenocarcinoma histology with specific morphologic patterns such as cribriform and solid signet ring, expression of thyroid transcription factor 1, tendency to metastasize to pleura or pericardium, frequently with more metastases than other molecular types, and predominantly metastases to the central nervous system.[56] The standard test used to detect this gene in tumor samples is fluorescence in situ hybridization (FISH) by a US FDA approved kit. Recently Roche Ventana obtained approval in China and European Union countries to test this mutation by immunohistochemistry.[57] Other techniques like reverse-transcriptase PCR (RT-PCR) can also be used to detect lung cancers with an ALK gene fusion but not recommended. ALK lung cancers are found in patients of all ages, although on average these patients tend to be younger. ALK lung cancers are more common in light cigarette smokers or nonsmokers, but a significant number of patients with this disease are current or former cigarette smokers. EML4-ALK-rearrangement in NSCLC is exclusive and not found in EGFR- or KRAS-mutated tumors.[58]

Gene rearrangements and overexpression in other tumours

ALK inhibitors

See main article: ALK inhibitor.

In patients affected by relapsed or refractory ALK+ Anaplastic Large Cell Lymphoma, crizotinib produced objective response rates ranging from 65% to 90% and 3 year progression free survival rates of 60-75%. No relapse of the lymphoma was ever observed after the initial 100 days of treatment. Treatment must be continued indefinitely at present.[74] [75] [76]

See also

Notes and references

Notes

  1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma . Science . 263 . 5151 . 1281–1284 . March 1994 . 8122112 . 10.1126/science.8122112 . 1994Sci...263.1281M .
  2. Web site: Entrez Gene: ALK anaplastic lymphoma kinase (Ki-1).
  3. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S . Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 . Oncogene . 9 . 6 . 1567–1574 . June 1994 . 8183550 .
  4. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T . Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system . Oncogene . 14 . 4 . 439–449 . January 1997 . 9053841 . 10.1038/sj.onc.1200849 . free .
  5. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, Witte DP . ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) . Oncogene . 14 . 18 . 2175–2188 . May 1997 . 9174053 . 10.1038/sj.onc.1201062 . free .
  6. Lorén CE, Scully A, Grabbe C, Edeen PT, Thomas J, McKeown M, Hunter T, Palmer RH . Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo . Genes to Cells . 6 . 6 . 531–544 . June 2001 . 11442633 . 1975818 . 10.1046/j.1365-2443.2001.00440.x .
  7. Liao EH, Hung W, Abrams B, Zhen M . An SCF-like ubiquitin ligase complex that controls presynaptic differentiation . Nature . 430 . 6997 . 345–350 . July 2004 . 15208641 . 10.1038/nature02647 . 4428538 . 2004Natur.430..345L .
  8. Yao S, Cheng M, Zhang Q, Wasik M, Kelsh R, Winkler C . Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish . PLOS ONE . 8 . 5 . e63757 . May 2013 . 23667670 . 3648509 . 10.1371/journal.pone.0063757 . free . 2013PLoSO...863757Y .
  9. Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH . FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase . eLife . 4 . e09811 . September 2015 . 26418745 . 4658194 . 10.7554/eLife.09811 . free .
  10. Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J . Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions . Proceedings of the National Academy of Sciences of the United States of America . 112 . 52 . 15862–15867 . December 2015 . 26630010 . 4702955 . 10.1073/pnas.1520099112 . free . 2015PNAS..11215862R .
  11. Zhang H, Pao LI, Zhou A, Brace AD, Halenbeck R, Hsu AW, Bray TL, Hestir K, Bosch E, Lee E, Wang G, Liu H, Wong BR, Kavanaugh WM, Williams LT . Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome . Proceedings of the National Academy of Sciences of the United States of America . 111 . 44 . 15741–15745 . November 2014 . 25331893 . 4226105 . 10.1073/pnas.1412009111 . free . 2014PNAS..11115741Z .
  12. Englund C, Lorén CE, Grabbe C, Varshney GK, Deleuil F, Hallberg B, Palmer RH . Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion . Nature . 425 . 6957 . 512–516 . October 2003 . 14523447 . 10.1038/nature01950 . 4425423 . 2003Natur.425..512E .
  13. Lee HH, Norris A, Weiss JB, Frasch M . Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers . Nature . 425 . 6957 . 507–512 . October 2003 . 14523446 . 10.1038/nature01916 . 4424062 . 2003Natur.425..507L .
  14. Reiner DJ, Ailion M, Thomas JH, Meyer BJ . C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling . Current Biology . 18 . 15 . 1101–1109 . August 2008 . 18674914 . 3489285 . 10.1016/j.cub.2008.06.060 . 2008CBio...18.1101R .
  15. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T . Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5) . Proceedings of the National Academy of Sciences of the United States of America . 93 . 9 . 4181–4186 . April 1996 . 8633037 . 39508 . 10.1073/pnas.93.9.4181 . free . 1996PNAS...93.4181F .
  16. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T . ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth . Journal of Cell Science . 117 . Pt 15 . 3319–3329 . July 2004 . 15226403 . 10.1242/jcs.01183 . free .
  17. Degoutin J, Vigny M, Gouzi JY . ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation . FEBS Letters . 581 . 4 . 727–734 . February 2007 . 17274988 . 10.1016/j.febslet.2007.01.039 . 40978851 . free .
  18. Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B . Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity . Blood . 103 . 4 . 1464–1471 . February 2004 . 14563642 . 10.1182/blood-2003-04-1038 . free .
  19. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R . The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration . Cancer Research . 67 . 9 . 4278–4286 . May 2007 . 17483340 . 10.1158/0008-5472.CAN-06-4350 . free .
  20. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity . Molecular and Cellular Biology . 18 . 12 . 6951–6961 . December 1998 . 9819383 . 109278 . 10.1128/mcb.18.12.6951 .
  21. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J . Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway . Blood . 96 . 13 . 4319–4327 . December 2000 . 11110708 . 10.1182/blood.V96.13.4319 .
  22. Gouzi JY, Moressis A, Walker JA, Apostolopoulou AA, Palmer RH, Bernards A, Skoulakis EM . The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning . PLOS Genetics . 7 . 9 . e1002281 . September 2011 . 21949657 . 3174217 . 10.1371/journal.pgen.1002281 . free .
  23. Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW . NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a . Blood . 103 . 12 . 4622–4629 . June 2004 . 14962911 . 10.1182/blood-2003-03-0820 . free .
  24. Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, Claret FX, Medeiros LJ, Amin HM . Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma . Blood . 105 . 2 . 827–829 . January 2005 . 15374880 . 1382060 . 10.1182/blood-2004-06-2125 .
  25. Ouyang T, Bai RY, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J . Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA) . The Journal of Biological Chemistry . 278 . 32 . 30028–30036 . August 2003 . 12748172 . 10.1074/jbc.M300883200 . free .
  26. Bassermann F, von Klitzing C, Münch S, Bai RY, Kawaguchi H, Morris SW, Peschel C, Duyster J . NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry . Cell . 122 . 1 . 45–57 . July 2005 . 16009132 . 10.1016/j.cell.2005.04.034 . 16122567 . free .
  27. Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, Payrastre B, Gaits-Iacovoni F . Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas . Oncogene . 27 . 19 . 2728–2736 . April 2008 . 17998938 . 10.1038/sj.onc.1210921 . free .
  28. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R . The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation . Cancer Research . 68 . 21 . 8899–8907 . November 2008 . 18974134 . 2596920 . 10.1158/0008-5472.CAN-08-2568 .
  29. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R . p130Cas mediates the transforming properties of the anaplastic lymphoma kinase . Blood . 106 . 12 . 3907–3916 . December 2005 . 16105984 . 1895100 . 10.1182/blood-2005-03-1204 .
  30. Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R . The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions . The Journal of Biological Chemistry . 285 . 26 . 19813–19820 . June 2010 . 20424160 . 2888392 . 10.1074/jbc.M110.121988 . free .
  31. Dupuis-Coronas S, Lagarrigue F, Ramel D, Chicanne G, Saland E, Gaits-Iacovoni F, Payrastre B, Tronchère H . The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness . The Journal of Biological Chemistry . 286 . 37 . 32105–32114 . September 2011 . 21737449 . 3173219 . 10.1074/jbc.M111.227512 . free .
  32. Palmer RH, Vernersson E, Grabbe C, Hallberg B . Anaplastic lymphoma kinase: signalling in development and disease . The Biochemical Journal . 420 . 3 . 345–361 . May 2009 . 19459784 . 2708929 . 10.1042/BJ20090387 .
  33. Hallberg B, Palmer RH . Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology . Nature Reviews. Cancer . 13 . 10 . 685–700 . October 2013 . 24060861 . 10.1038/nrc3580 . 21345361 .
  34. Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B . Characterization of the expression of the ALK receptor tyrosine kinase in mice . Gene Expression Patterns . 6 . 5 . 448–461 . June 2006 . 16458083 . 10.1016/j.modgep.2005.11.006 .
  35. Souttou B, Carvalho NB, Raulais D, Vigny M . Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway . The Journal of Biological Chemistry . 276 . 12 . 9526–9531 . March 2001 . 11121404 . 10.1074/jbc.M007333200 . free .
  36. Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J, Créminon C, Vigny M . Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin . The Journal of Biological Chemistry . 280 . 28 . 26039–26048 . July 2005 . 15886198 . 10.1074/jbc.M501972200 . free .
  37. Gouzi JY, Moog-Lutz C, Vigny M, Brunet-de Carvalho N . Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells . Journal of Cell Science . 118 . Pt 24 . 5811–5823 . December 2005 . 16317043 . 10.1242/jcs.02695 . free .
  38. Stute C, Schimmelpfeng K, Renkawitz-Pohl R, Palmer RH, Holz A . Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways(mili(Alk)) as receptor for Jeb signalling . Development . 131 . 4 . 743–754 . February 2004 . 14757637 . 10.1242/dev.00972 . free .
  39. Bilsland JG, Wheeldon A, Mead A, Znamenskiy P, Almond S, Waters KA, Thakur M, Beaumont V, Bonnert TP, Heavens R, Whiting P, McAllister G, Munoz-Sanjuan I . Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications . Neuropsychopharmacology . 33 . 3 . 685–700 . February 2008 . 17487225 . 10.1038/sj.npp.1301446 . free .
  40. Weiss JB, Xue C, Benice T, Xue L, Morris SW, Raber J . Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis . Pharmacology, Biochemistry, and Behavior . 100 . 3 . 566–574 . January 2012 . 22079349 . 10.1016/j.pbb.2011.10.024 . 2386055 .
  41. Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH . Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism . PLOS ONE . 10 . 5 . e0123542 . May 2015 . 25955180 . 4425494 . 10.1371/journal.pone.0123542 . free . 2015PLoSO..1023542W .
  42. Bazigou E, Apitz H, Johansson J, Lorén CE, Hirst EM, Chen PL, Palmer RH, Salecker I . Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila . Cell . 128 . 5 . 961–975 . March 2007 . 17350579 . 10.1016/j.cell.2007.02.024 . 10341647 . free .
  43. Cheng LY, Bailey AP, Leevers SJ, Ragan TJ, Driscoll PC, Gould AP . Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila . Cell . 146 . 3 . 435–447 . August 2011 . 21816278 . 10.1016/j.cell.2011.06.040 . 4287148 . free .
  44. Rohrbough J, Broadie K . Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap . Development . 137 . 20 . 3523–3533 . October 2010 . 20876658 . 2947762 . 10.1242/dev.047878 .
  45. Rohrbough J, Kent KS, Broadie K, Weiss JB . Jelly Belly trans-synaptic signaling to anaplastic lymphoma kinase regulates neurotransmission strength and synapse architecture . Developmental Neurobiology . 73 . 3 . 189–208 . March 2013 . 22949158 . 3565053 . 10.1002/dneu.22056 .
  46. Lasek AW, Lim J, Kliethermes CL, Berger KH, Joslyn G, Brush G, Xue L, Robertson M, Moore MS, Vranizan K, Morris SW, Schuckit MA, White RL, Heberlein U . An evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol . PLOS ONE . 6 . 7 . e22636 . Jul 2011 . 21799923 . 3142173 . 10.1371/journal.pone.0022636 . free . 2011PLoSO...622636L .
  47. Schweitzer P, Cates-Gatto C, Varodayan FP, Nadav T, Roberto M, Lasek AW, Roberts AJ . Dependence-induced ethanol drinking and GABA neurotransmission are altered in Alk deficient mice . Neuropharmacology . 107 . 1–8 . August 2016 . 26946429 . 4912883 . 10.1016/j.neuropharm.2016.03.003 .
  48. Dutton JW, Chen H, You C, Brodie MS, Lasek AW . Anaplastic lymphoma kinase regulates binge-like drinking and dopamine receptor sensitivity in the ventral tegmental area . Addiction Biology . 22 . 3 . 665–678 . May 2017 . 26752591 . 4940304 . 10.1111/adb.12358 .
  49. Mangieri RA, Maier EY, Buske TR, Lasek AW, Morrisett RA . Anaplastic Lymphoma Kinase Is a Regulator of Alcohol Consumption and Excitatory Synaptic Plasticity in the Nucleus Accumbens Shell . Frontiers in Pharmacology . 8 . 533 . Aug 2017 . 28860990 . 5559467 . 10.3389/fphar.2017.00533 . free .
  50. Bai L, Sehgal A . Anaplastic Lymphoma Kinase Acts in the Drosophila Mushroom Body to Negatively Regulate Sleep . PLOS Genetics . 11 . 11 . e1005611 . November 2015 . 26536237 . 4633181 . 10.1371/journal.pgen.1005611 . free .
  51. Gouzi JY, Bouraimi M, Roussou IG, Moressis A, Skoulakis EM . The Drosophila Receptor Tyrosine Kinase Alk Constrains Long-Term Memory Formation . The Journal of Neuroscience . 38 . 35 . 7701–7712 . August 2018 . 30030398 . 6705970 . 10.1523/JNEUROSCI.0784-18.2018 .
  52. Woodling NS, Aleyakpo B, Dyson MC, Minkley LJ, Rajasingam A, Dobson AJ, Leung KH, Pomposova S, Fuentealba M, Alic N, Partridge L . The neuronal receptor tyrosine kinase Alk is a target for longevity . Aging Cell . 19 . 5 . e13137 . May 2020 . 32291952 . 7253064 . 10.1111/acel.13137 . free .
  53. Orthofer M, Valsesia A, Mägi R, Wang QP, Kaczanowska J, Kozieradzki I, Leopoldi A, Cikes D, Zopf LM, Tretiakov EO, Demetz E, Hilbe R, Boehm A, Ticevic M, Nõukas M, Jais A, Spirk K, Clark T, Amann S, Lepamets M, Neumayr C, Arnold C, Dou Z, Kuhn V, Novatchkova M, Cronin SJ, Tietge UJ, Müller S, Pospisilik JA, Nagy V, Hui CC, Lazovic J, Esterbauer H, Hagelkruys A, Tancevski I, Kiefer FW, Harkany T, Haubensak W, Neely GG, Metspalu A, Hager J, Gheldof N, Penninger JM . Identification of ALK in Thinness . Cell . 181 . 6 . 1246–1262.e22 . June 2020 . 32442405 . 10.1016/j.cell.2020.04.034 . 218762956 . free .
  54. In 2020, a genome-wide association study (GWAS) was published of 47,102 people in the Estonian Genome Center of the University of Tartu (EGCUT) Biobank which compared the DNA of healthy thin individuals in the lowest 6th percentile of body mass index to the DNA of normal-weight individuals. This study identified a number of genetic variations of the ALK gene that were associated with thinness. As a next step, experiments in mice and Drosophila fruit flies showed that mice in which the ALK gene was knocked out had the similar activity and diet levels as normal mice, but had lower body fat and weight from early age into adulthood. This implies that inhibition of this kinase, already of interest as a chemotherapy for cancers associated with this gene, might be a way to prevent weight gain.
  55. Mologni L . Inhibitors of the anaplastic lymphoma kinase . Expert Opinion on Investigational Drugs . 21 . 7 . 985–994 . July 2012 . 22612599 . 10.1517/13543784.2012.690031 . 24564015 .
  56. Patcas A, Chis AF, Militaru CF, Bordea IR, Rajnoveanu R, Coza OF, Hanna R, Tiberiu T, Todea DA . An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance . Bosnian Journal of Basic Medical Sciences . 22 . 1 . 1–13 . February 2022 . 34082691 . 8860314 . 10.17305/bjbms.2021.5859 .
  57. Web site: VENTANA ALK (D5F3) CDx Assay. Diagnostics.
  58. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D . International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma . Journal of Thoracic Oncology . 6 . 2 . 244–285 . February 2011 . 21252716 . 4513953 . 10.1097/JTO.0b013e318206a221 .
  59. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM . Identification of ALK as a major familial neuroblastoma predisposition gene . Nature . 455 . 7215 . 930–935 . October 2008 . 18724359 . 2672043 . 10.1038/nature07261 . 2008Natur.455..930M .
  60. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P . Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor . Genes, Chromosomes & Cancer . 34 . 4 . 354–362 . August 2002 . 12112524 . 10.1002/gcc.10033 . 22808049 .
  61. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA . TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors . The American Journal of Pathology . 157 . 2 . 377–384 . August 2000 . 10934142 . 1850130 . 10.1016/S0002-9440(10)64550-6 .
  62. Sukov WR, Hodge JC, Lohse CM, Akre MK, Leibovich BC, Thompson RH, Cheville JC . ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients . Modern Pathology . 25 . 11 . 1516–1525 . November 2012 . 22743654 . 10.1038/modpathol.2012.107 . free .
  63. Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K . Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method . Cancer . 118 . 18 . 4427–4436 . September 2012 . 22252991 . 10.1002/cncr.27391 . 9387860 . free .
  64. Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA . Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum . Modern Pathology . 24 . 3 . 430–442 . March 2011 . 21076462 . 10.1038/modpathol.2010.213 . free .
  65. Mariño-Enríquez A, Ou WB, Weldon CB, Fletcher JA, Pérez-Atayde AR . ALK rearrangement in sickle cell trait-associated renal medullary carcinoma . Genes, Chromosomes & Cancer . 50 . 3 . 146–153 . March 2011 . 21213368 . 10.1002/gcc.20839 . 39004672 .
  66. Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH . Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer . World Journal of Gastroenterology . 12 . 44 . 7104–7112 . November 2006 . 17131471 . 4087770 . 10.3748/wjg.v12.i44.7104 . free .
  67. Yaakup H, Sagap I, Fadilah SA . Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype . Singapore Medical Journal . 49 . 10 . e289–e292 . October 2008 . 18946602 .
  68. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z . Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers . Molecular Cancer Research . 7 . 9 . 1466–1476 . September 2009 . 19737969 . 10.1158/1541-7786.MCR-08-0522 . free .
  69. Tuma RS . ALK gene amplified in most inflammatory breast cancers . Journal of the National Cancer Institute . 104 . 2 . 87–88 . January 2012 . 22215853 . 10.1093/jnci/djr553 . free .
  70. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A . Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth . The Journal of Biological Chemistry . 277 . 16 . 14153–14158 . April 2002 . 11809760 . 10.1074/jbc.M112354200 . free .
  71. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, Wellstein A . Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin . The Journal of Biological Chemistry . 276 . 20 . 16772–16779 . May 2001 . 11278720 . 10.1074/jbc.M010660200 . free .
  72. Murugan AK, Xing M . Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene . Cancer Research . 71 . 13 . 4403–4411 . July 2011 . 21596819 . 3129369 . 10.1158/0008-5472.CAN-10-4041 .
  73. Web site: Xalkori Approved for Lung Cancer. FDA.
  74. Gambacorti-Passerini CB, Dilda I, Giudici G, Perego A, Pavesi F, Guerra L, Borin L, Casaroli I, Fedele M, Verga L, Pogliani EM . Clinical activity of crizotinib in advanced, chemoresistant ALK+ lymphoma patients. . 2010 Annual Meeting of the American Society of Hematology . Orlando, Florida .
  75. Gambacorti-Passerini C, Messa C, Pogliani EM . Crizotinib in anaplastic large-cell lymphoma . The New England Journal of Medicine . 364 . 8 . 775–776 . February 2011 . 21345110 . 10.1056/NEJMc1013224 . free .
  76. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R . Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients . Journal of the National Cancer Institute . 106 . 2 . djt378 . February 2014 . 24491302 . 10.1093/jnci/djt378 . free .
  77. Web site: ZYKADIA (ceritinib) capsules, for oral use Initial U.S. Approval: 2014 . United States Food and Drug Administration .

References

Further reading

External links

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anaplastic lymphoma kinase".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.